The alleviating effect of EPA-PC on non-alcoholic fatty liver disease was tested.
EPA-PC regulated key enzyme activities in fatty acid synthesis, transport and β-oxidation.
The mechanism involved regulating transcriptions of AMPK and its target genes.
Our study predicted EPA-PC as a novel agent for non-alcoholic fatty liver disease.